Navigation Links
Eurofins Genomics US Announces Commercial Launch of Next Generation DNA Synthesis Service
Date:3/14/2017

LOUISVILLE, Ky., March 14, 2017 /PRNewswire/ -- Eurofins Genomics, the pioneer of high-throughput oligonucleotide synthesis, announced the U.S. commercial launch of a unique DNA synthesis service based on the company's revolutionary next-generation synthesis platform. The service, which is designed to supply small quantities of high-quality oligos for use in molecular biology and synthetic biology, among other applications, allows users to receive high-fidelity, QC-verified oligos for low cost and with industry-leading turnaround.

Standard approaches to synthesizing oligonucleotides—commonly used as primers for PCR, qPCR, and next-generation sequencing-based workflows—produce much more DNA than scientists need, forcing them to pay for excess material that will never be used. The new Eurofins Genomics synthesis platform was engineered for scalability, producing both small synthesis scale (down to 0.5 nanomoles) to very large orders of DNA. By allowing scientists to choose how much DNA to buy, this service will reduce costs and enable users to perform more experiments on the same budget.

Eurofins Genomics has made a series of recent improvements to its oligo synthesis services. In the U.S. and Canada, orders for oligos meeting the specified scale, length and purification criteria and placed as late as 5:00 p.m. are eligible for same-day synthesis and overnight shipping for no additional surcharge. The company also launched EXTREmer oligonucleotides, extremely long oligos produced at low yield and with low error rates, which are ideal for synthetic biology and CRISPR experiments. In addition, the company has expanded the hours of operation for its service lab to include Sundays, so is now running seven days a week and virtually around the clock to ensure reliability for customers.   

"By completely reimagining the synthesis process, including applying tenants of aerospace engineering, we have created a new platform that will help users accelerate their science while ensuring the quality and reliability of their results," said Martin Kunz, President, Eurofins Genomics US. "We have been very encouraged by feedback about our next-generation synthesis technology from customers in our beta program and are pleased to expand its availability to more scientists in the U.S."

To learn more about all of the products and services offered by Eurofins Genomics, visit www.eurofinsgenomics.com.

About Eurofins Genomics

Eurofins Genomics company is an international provider of DNA sequencing services, genotyping services, DNA synthesis products, and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological, and research markets. Eurofins Genomics operates leading R&D and production sites in the USA, Canada, Germany, India, and Japan.

Eurofins Genomics is the genomic services brand of the Eurofins Group, the worldwide leader in food, environmental and pharmaceutical testing. With EUR 2.54 billion in annual revenues and over 27,000 employees across over 310 sites in 39 countries, Eurofins Scientific is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

© Eurofins MWG Operon, LLC. A Eurofins Genomics Company

Contacts:

Media:
Nicole Litchfield
Bioscribe, Inc.
415-793-6468
nicole@bioscribe.com

Company:
James Corne
Eurofins Genomics
502-302-6351
jamescorne@eurofins.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eurofins-genomics-us-announces-commercial-launch-of-next-generation-dna-synthesis-service-300423119.html


'/>"/>
SOURCE Eurofins Genomics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
2. SimpleSeq Webless by Eurofins MWG Operon for Order-Free DNA Sequencing
3. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
4. Eurofins MWG Operon, Inc. Names James Corne as Director of Marketing
5. Eurofins Pharma Discovery Services Launches New eCommerce Platform for Drug Discovery Products
6. Eurofins Microbiology Opens State-of-the-Art Laboratory in Louisville, KY
7. Eurofins Genomics Looks to Disrupt DNA Synthesis Market with Smaller-Scale, High-Throughput Service Featuring Rapid Turnaround and Lower Price
8. Clarification on Eurofins Scientific, Inc. (US) Announcement of the Appointment of Sean Murray
9. Eurofins Genomics Launches EXTREmers - Extremely Long Oligonucleotides
10. Eurofins Genomics Expands Express Oligo Service
11. Genomics Data Management Leader Annai Systems Offers Shortcut to Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
Breaking Biology News(10 mins):